Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up?
02:00pm, Friday, 20'th Mar 2026
Novo Nordisk unveiled a troubling guidance for 2026, which tanked the stock. It recently reached a deal with telehealth company Hims & Hers Health to sell its GLP-1 products.
What's Going On With Novo Nordisk Friday
11:56am, Friday, 20'th Mar 2026
Novo Nordisk (NVO) fell about 2% on early Friday even after the U.S. Food and Drug Administration approved a higher-dose version of its obesity treatment Wegovy
FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients
09:10am, Friday, 20'th Mar 2026
NVO wins FDA's accelerated nod for a higher 7.2 mg Wegovy dose, backed by strong phase III weight-loss data, with a U.S. launch planned for April 2026.
China expresses hopes over Novo Nordisk's presence in market
09:01am, Friday, 20'th Mar 2026
China hopes Novo Nordisk will "continue to cultivate the Chinese market and contribute to building a healthy China," said Ling Ji, China's vice commerce minister, duri
The Dow's losing streak, fertilizer prices, Novo Nordisk's new Wegovy shot and more in Morning Squawk
08:30am, Friday, 20'th Mar 2026
Here are five key things investors need to know to start the trading day.
Lilly GLP-1 drug rivals Novo's pipeline treatment on gut side effects but throws up skin concern
07:15am, Friday, 20'th Mar 2026
New trial data complicates the competitive picture in the fast-growing obesity drug market Eli Lilly and Co's (NYSE:LLY) experimental weight-loss and diabetes drug retatrutide has shown a side-effect
Novo Nordisk Wins U.S. Approval for Higher-Dose Wegovy
07:08am, Friday, 20'th Mar 2026
Novo Nordisk (NVO, Financials) has gotten the go-ahead from the U.S. to sell a stronger version of its popular obesity medicine. Wegovy is a new alternative for
India's weight-loss drug boom: Novo Nordisk talks about GLP-1 generics after patent expiry
03:23am, Friday, 20'th Mar 2026
The patent on semaglutide, found in Novo Nordisk's Ozempic and Wegovy weight-loss drugs, expired in India on March 20. Vikrant Shrotriya, managing director at Novo Nordisk India, talks about how gener
A high dose of Wegovy helped people lose 21% of their weight. It was just approved.
02:42pm, Thursday, 19'th Mar 2026
Novo Nordisk's 7.2 mg dose of Wegovy will compete against Lilly's GLP-1 injection.
Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy
01:50pm, Thursday, 19'th Mar 2026
• Novo Nordisk shares are experiencing downward pressure. What's pulling NVO shares down?
Novo Nordisk's Higher Dose Wegovy Weight-Loss Drug Gains U.S. Approval
12:57pm, Thursday, 19'th Mar 2026
The Danish drugmaker said the accelerated approval was based on results from its Step Up trial, which showed 20.7% mean weight loss for participants with obesity.
FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share
12:53pm, Thursday, 19'th Mar 2026
The Food and Drug Administration approved a higher dose version of Novo Nordisk's blockbuster weight loss injection Wegovy, as the company pushes to win back market share from Eli Lilly. The high-dose
Average weight loss of ~21% at 72 weeks in adults with obesity if all patients stayed on treatment* with Wegovy ® HD (~19% regardless of whether patients stayed on treatment**) in the STEP UP trial1
US FDA approves higher dose of Wegovy
11:51am, Thursday, 19'th Mar 2026
Novo Nordisk said on Thursday the U.S. Food and Drug Administration has approved a high dose of Wegovy to reduce excess body weight and maintain weight reduct
Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss
11:40am, Thursday, 19'th Mar 2026
Wegovy® HD demonstrated a mean weight loss of 20.7%1, and around one-third of patients achieved 25% or greater weight loss in the STEP UP trial First US FDA approval of a GLP-1 treatment under the Co
